Join us on May 10, 2021 for the 10th annual Ependymoma Awareness Day!
Join us on May 10, 2021 for the 10th annual Ependymoma Awareness Day!
Share this:

Ependymoma Awareness Day is May 10, 2021

Join us for Ependymoma Awareness Day.

Support the Ependymoma Awareness Day Campaign!

Support the Ependymoma Awareness Day campaign by making a donation or creating your own personal online EAD fundraising page! For each donation over $25, a butterfly will be released during the EAD ceremony. All donations will go to the Ependymoma Fund for Education and Research supported by the National Brain Tumor Society.

Patients, care partners and medical professionals from around the world dedicate May 10, 2021 as the 10th annual Ependymoma Awareness Day!

Join the CERN Foundation and the National Brain Tumor Society during Brain Tumor Awareness Month to commemorate the 2021 Ependymoma Awareness Day! This year Ependymoma Awareness Day will be held on May 10th to represent the 10 different molecular groups of ependymoma. Held every year since 2012 as a global advocacy event, Ependymoma Awareness Day highlights the importance of an accurate diagnosis and the urgent need for better targeted treatments.
On Ependymoma Awareness Day, butterflies around the world are released to honor loved ones with ependymoma, recognize care partners and medical workers, and to support ependymoma research efforts. The delicate and beautiful butterfly was chosen to represent the spirit of the ependymoma community as a symbol of hope through change. Join CERN on May 10 for Ependymoma Awareness Day!
Ependymoma Awareness Day (EAD) was established in 2012 by the CERN Foundation as part of a global effort to shine a light on this poorly understood disease. Our goal with Ependymoma Awareness Day is to increase public recognition of this rare tumor and the urgent need for more clinical studies to improve diagnostic methods, develop better targeted treatments and improve outcomes for those living with this disease.
Read more about EAD!

Scientific Spotlight: Eric Holland

Major Discoveries and Sustained Focus Lead to Big Pay-off
CERN-funded research culminates in $6M in government funding to develop treatments targeting fusion found in 70% of supratentorial ependymomas.
“Sometimes it’s the rare things that teach us about the common ones,” says Dr. Eric Holland, a world-renowned neurosurgeon and brain tumor researcher at the Fred Hutchinson Cancer Research Center (the Hutch) and University of Washington (UW) Medicine.
 
Make a gift
Support the Ependymoma Fund for Research and Education
With your generous support, we will continue to expand our efforts to improve the care and outcome of people with ependymoma. Under “Direct My Gift to Support,” remember to select the Ependymoma Research and Education Fund.
Make A Gift
  Make a gift
The CERN Foundation and the National Brain Tumor Society have joined forces to help people with ependymoma and advance ependymoma research toward the development of new and better treatments through the creation of the Ependymoma Fund for Research and Education. Today, the CERN Foundation is officially a designated program of the National Brain Tumor Society. Donations to the Ependymoma Fund for Research and Education will be made on the NBTS website and used to support research efforts that will benefit both ependymoma patients and research through CERN. Emphasis will be placed on CERN’s historical model of supporting work that translates basic science into clinical practice. The Fund will also address overcoming barriers to clinical trial accrual and the development of new clinical studies for ependymoma patients. Additional funds will be used to support educational efforts through print, media, and awareness events. The new collaborative Ependymoma Fund will continue CERN’s practice and tradition of involving and collaborating with other scientists, medical providers, foundations and supporters of ependymoma research.
Follow us.
Friend us.
Pinterest
Follow us.
CERN Foundation PO Box 217 | Zionsville, IN 46077 US
powered by emma
Subscribe to our email list.